References
- Rheumatoid arthritis and tuberculosis: Time to take notice. Gardam M, Iverson K. s.l. : The Journal of Rheumatology, 2003, Vol. 30:7, pp. 1397–1399.
- Tuberculosis comorbidity with rheumatoid arthritis: Gene signatures, associated biomarkers and screening. Zafari P, Golpour M, Hafezi N, Bashash D, Esmaeili S.A, Tavakolinia N et al. s.l. : IUBMB Life, 2021, Vol. 73, pp. 26–39.
- Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis receiving non anti-TNF-targeted biologics. Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D. s.l. : Hindawi-Mediators of inflammation, 2017, pp. 1–15.
- Methotrexate and reactivation tuberculosis. S.R, Lamb. s.l. : Journal of the American Academi of Dermatology, 2004, Vol. 51, pp. 481–482.
- Leflunomide-associated tuberculosis? Hocevar A, Rozman B, Praprotnik S, Lestan B, Erzen D, Petric V et al. s.l. : Rheumatology-Letters to the Editor, 2006, Vol. 45, pp. 228–229.
- Latent tuberculosis infection in RA: The disease and the diagnosis. Metha B, Efthimiou P. s.l. : The journal of musculoskeletal medicine, 2011, Vol. 28.
- Antirheumatic drugs and the risk of tuberculosis. Brassard P, Kezouh A, Suissa S. s.l. : Clinical Infectious Diseases, 2006, Vol. 43, pp. 717–722.
- Miliary tuberculosis in a rheumatoid arthritis patient receiving long-term tumor necrosis factor monoclonal antibody therapy. Wang C.R, Lin W.C, Tsai Y.S. 2021, Vol. 27, pp. 364–366.
- Safety analyses of adalimumab in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Schiff M.H, Burmester G.R, Kent J.D, Pagan A.L, Kupper H, Fitzpatrick S.B et al. s.l. : Annals of Rheumatic diseases, 2006, Vol. 65, pp. 889–894.
- Miliary Tuberculosis. Vohra S, Dhaliwal HS. s.l. : StatPearls Publishing, Treasure Island, 2022.